Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Next Previous
X
Search
Trial Profile

Phase 1/2a, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone decanoate (Primary) ; Dexamethasone; Docetaxel; Prednisone; Steroids
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma; Propella Therapeutics

    • Most Recent Events

    • 07 Mar 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 27 Jan 2024 Interim results of data that includes the provisional RP2D and data from patients with prior exposure to enzalutamide recruited in either dose escalation or a dedicated expansion cohort presented at the 2024 Genitourinary Cancers Symposium.
    • 21 Dec 2023 According to a Astellas Pharma Inc. media release, company completed acquisition of Propella Therapeutics, Inc. and has become a wholly owned subsidiary of Astellas. Through the acquisition of Propella, Astellas has acquired PRL-02 (abiraterone decanoate), being developed by Propella to treat prostate cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top